Sanofi's assault on Aventis galvanises capital markets
Sanofi-Synthélabo, the French pharmaceuticals company, lit up the bond, equity and loan markets this week by launching a Eu47.8bn hostile bid for its competitor, Aventis.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: